No abstract

Consistent with data from the white population with uterine leiomyoma, our data showed a significantly higher BMD in African-American women with uterine leiomyoma, compared with an age- and race-matched cohort. The implications of these findings remain to be investigated and further confirmed in future longitudinal studies.

No abstract

No abstract

Home PD, Pocock SJ, Beck-Nielsen H, et al. : Rosiglitazone evaluated for cardiovascular outcomesan interim analysis. N Engl J Med 2007, 357: 28-38. Rating: •• Of major importance.Introduction: Rosiglitazone, a thiazolidinedione (TZD), was approved in 1999 for treating hyperglycemia in type 2 diabetes [ 1 ]. In addition to its benefi cial effects on hepatic and peripheral insulin sensitivity [ 2 ], TZDs are thought to have cardiovascular benefi ts above and beyond the glucose-lowering effects. The mechanism of these presumed benefi cial cardiovascular effects involves antiatherosclerotic and anti-infl ammatory changes together with potential effects on dyslipidemia, visceral obesity, hypertension, and microalbuminuria [ 3 , 4 ]. However, a recent meta-analysis by Nissen and Wolski [ 5 ] raised concern about the cardiovascular safety of rosiglitazone treatment of type 2 diabetes. It suggested that rosiglitazone increased the risk of myocardial infarction by 43% and might also increase the risk of cardiovascular mortality. This meta-analysis generated a substantial amount of discussion regarding the cardiovascular safety of TZDs, prompting the RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of glycemia in diabetes) study investigators to perform an unplanned analysis of the interim study results to assess the study's cardiovascular outcomes. We review the results of the interim analysis of the RECORD trial and highlight the implications of the cardiovascular outcomes on the current TZD debate.